Drug Trial Radar · NCT06900543
Chinese HCC Efficacy Evaluation, Response and Safety Study of TareSphere
Last checked: Nov 19, 2026Latest source record: Jun 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
108
Planned (sponsor's estimate)
Start
Apr 15, 2025
Primary completion
Oct 2027
Study completion Dec 2027
Sponsor
- Lead sponsor
- Chengdu New Radiomedicine Technology Co. LTD.Industry
- Sponsor type
- Industry
- First posted
- Mar 28, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to evaluate the efficacy and safety of NRT6003 Injection compared to cTACE in patients with unresectable HCC.
Conditions
- Unresectable Hepatocellular Carcinoma
Interventions
NRT6003 InjectionDrug
Patients will be administered NRT6003 Injection via Intra-arterial infusion, and subsequently they will be assessed by PET/CT imaging within 24 hours for its distribution in the chest and upper abdomen, including extrahepatic shunts, intrahepatic distribution, and target lesion distribution as expected.
cTACEDrug
Patients will receive cTACE treatment. And the investigators will select one or more chemotherapy drugs in combination with embolic materials for administration, based on the specific condition of the patient.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to Progression (TTP)Time frame: Through study completion, at least 18 months
Locations
19 sites in 1 country. Site status is shown where the registry gives one.
The First Hospital Affiliated to the Army Medical University
Chongqing, China
The First Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, China
Zhongshan Hospital Fudan University
Shanghai, China
Fujian Cancer Hospital
Fuzhou, Fujian, China
Mengchao Hepatobiliary Hospital of Fujian Medical University
Fuzhou, Fujian, China
The First Affiliated Hospital of Fujian Medical University
Fuzhou, Fujian, China
The First Affiliated Hospital of Jinan University
Guangzhou, Guangdong, China
The Second Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China
The Third Affiliated Hospital of Sun Yat-sen University
Guangzhou, Guangdong, China
Henan Cancer Hospital
Zhengzhou, Henan, China
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China
Zhongnan Hospital of Wuhan University
Wuhan, Hubei, China
Zhongda Hospital Southeast University
Nanjing, Jiangsu, China
The First Hospital of China Medical University
Shenyang, Liaoning, China
Xi'an International Medical Center Hospital
Xi’an, Shanxi, China
West China Hospital
Chengdu, Sichuan, China
The Affiliated Hospital of Southwest Medical University
Luzhou, Sichuan, China
Tianjin Cancer Hospital Airport Hospital
Tianjin, Tianjin Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.